JNJJohnson & Johnson

Health care · Pharmaceuticals · NYSE

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. 10-K, Item 1

Headquarters: New Brunswick, NJ
CEO: Joaquin Duato
Next results: around Jan 20, 2027

Compare with peers → Embed

RevenueFY2016–25 $94.2B+6.0% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $26.8B+90.6% FY2024: $14.1B 10-K FY2025 · XBRL Free cash flowFY2016–25 $19.7B−0.7% FY2024: $19.8B 10-K FY2025 · XBRL

What changed

10-K filed Feb 11, 2026 against Feb 13, 2025

Area	What changed	Source
Risk factors	6 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Cash from operations lower than net income	Cash from operations $24.5B vs net income $26.8B (FY ending 2025-12-28)	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 11, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-13. Quoted as filed.

The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results In October 2025, the Company announced its intention to separate the Company's Orthopaedics business. The Company is targeting completion of the planned…
10-K, Item 1A

All 6 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Cash from operations lower than net incomeCash from operations $24.5B vs net income $26.8B (FY ending 2025-12-28)
✓
Receivables +15.7% vs revenue +6.0% (+9.7 pts)
✓
Inventory +14.0% vs revenue +6.0% (+8.0 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: U.S. Innovative Medicine Rebate Reserves - Managed Care, Medicare and Medicaid; Litigation Contingencies - Talc
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Oct 21, 202610-Q Quarterly report (10-Q) period ended Sep 27, 2026
Oct 13, 20268-K Quarterly results 8-K item 2.02

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on JNJ in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/JNJ/export.csv") into a cell.